FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer

[1]  Saugata Hazra,et al.  The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective , 2019, Journal of cellular physiology.

[2]  S. Yano,et al.  Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer , 2017, Carcinogenesis.

[3]  H. Nakagawa,et al.  Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma , 2017, Carcinogenesis.

[4]  S. Hanash,et al.  MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. , 2017, Cancer research.

[5]  H. Sugiyama,et al.  A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm , 2017, Nucleic acids research.

[6]  J. Thiery,et al.  New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.

[7]  Roman K. Thomas,et al.  Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer , 2017, Clinical Cancer Research.

[8]  M. Berger,et al.  A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers , 2017, Clinical Cancer Research.

[9]  S. Paik,et al.  Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W. Xia,et al.  FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells , 2017, Journal of experimental & clinical cancer research : CR.

[11]  J. Slingerland,et al.  VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug , 2017, Oncogene.

[12]  A. Nielsen,et al.  MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells , 2017, Oncogenesis.

[13]  J. Datta,et al.  Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 , 2017, Molecular Cancer Therapeutics.

[14]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Katoh.  Therapeutics Targeting FGF Signaling Network in Human Diseases. , 2016, Trends in pharmacological sciences.

[16]  A. Mintz,et al.  Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer , 2016, Oncotarget.

[17]  A. Berns,et al.  SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin , 2016, Cancer cell.

[18]  J. Ahn,et al.  Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study , 2016, Cancer.

[19]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[20]  Yiling Lu,et al.  Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer , 2016, Oncogene.

[21]  M. Mino‐Kenudson,et al.  Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression , 2016, Oncogene.

[22]  Michael K. Wendt,et al.  Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer , 2016, Molecular Cancer Therapeutics.

[23]  L. Carvalho,et al.  Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma , 2016, Virchows Archiv.

[24]  K. Strebhardt,et al.  Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy , 2016, Oncogene.

[25]  Philippe Soriano,et al.  Genetic insights into the mechanisms of Fgf signaling , 2016, Genes & development.

[26]  Elisa de Stanchina,et al.  Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT , 2016, Cell.

[27]  W. Xia,et al.  Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients , 2016, Oncotarget.

[28]  W. Xia,et al.  FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway , 2016, Oncotarget.

[29]  H. Yang,et al.  Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial–mesenchymal transition in non-small-cell lung cancer , 2016, Oncogene.

[30]  Katherine R. Singleton,et al.  Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. , 2015, Cancer research.

[31]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[33]  A. Jimeno,et al.  FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers , 2015, Clinical Cancer Research.

[34]  W. Kim,et al.  US lung cancer trends by histologic type , 2015, Cancer.

[35]  S. Knapp,et al.  Abstract IA09: Copper is required for oncogenic BRAF signaling and tumorigenesis , 2014 .

[36]  H. Gu,et al.  Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. , 2014, Biomaterials.

[37]  R. Mumper,et al.  Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[38]  D. R. Lewis,et al.  US lung cancer trends by histologic type , 2014, Cancer.

[39]  J. Utikal,et al.  SOX2 and cancer: current research and its implications in the clinic , 2014, Clinical and Translational Medicine.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[41]  S. Rorive,et al.  SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma , 2014, Nature.

[42]  P. Jänne,et al.  Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease , 2014, PloS one.

[43]  Jih-Hsiang Lee,et al.  Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  H. Nakagama,et al.  FGF Receptors: Cancer Biology and Therapeutics , 2014, Medicinal research reviews.

[45]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[46]  M. Walsh,et al.  The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. , 2014, Cancer cell.

[47]  J. Wolf,et al.  Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer , 2014, Modern Pathology.

[48]  Roman K. Thomas,et al.  Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. , 2014, Cancer discovery.

[49]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[50]  G. Getz,et al.  A Genomics-Based Classification of Human Lung Tumors , 2013, Science Translational Medicine.

[51]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[52]  S. Ha,et al.  Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[54]  K. Hochedlinger,et al.  The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. , 2013, Cell stem cell.

[55]  Roman K. Thomas,et al.  Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models , 2012, Clinical Cancer Research.

[56]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[57]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[58]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[59]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[60]  Andrew P Thomas,et al.  AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. , 2012, Cancer research.

[61]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[62]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[63]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[64]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[65]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[66]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[67]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[68]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[69]  N. Hanna,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. , 2017, Journal of oncology practice.

[70]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[71]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[72]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[73]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.